Inpharmica Overview

  • Founded
  • 2015

  • Status
  • Private

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $356K

  • Investors
  • 1

Inpharmica General Information


Developer of a bio-medicine technology designed to aid complex painkiller drug development. The company's technology is used in performing phase III of clinical studies on an increased number of patients, including the monitoring of undesired effects and the development of documentation to register a new complex painkiller patented, enabling patients to access next-generation pain-killers.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • Ul. Czerwonych Maków 12 lok. 13
  • Warsaw, Mazowieckie
  • Poland
+48 600 000 000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Inpharmica Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Seed Round 18-Dec-2015 $356K 00000 Completed Generating Revenue
To view Inpharmica’s complete valuation and funding history, request access »

Inpharmica Executive Team (1)

Name Title Board Seat Contact Info
Dorota Święcicka Executive
To view Inpharmica’s complete executive team members history, request access »

Inpharmica Board Members (2)

Name Representing Role Since
Szczepan Adamski Inpharmica Chairman 000 0000
Weronika Kiełczewska Inpharmica Board Member 000 0000
To view Inpharmica’s complete board members history, request access »

Inpharmica Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Black Pearls VC Venture Capital Minority 000 0000 000000 0
To view Inpharmica’s complete investors history, request access »